MeSH D010911 - pituitary neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Mylan | Octreotide | Octreotide | 2011-02-10 | |||
| Novartis | Octreotide | Sandostatin | 1988-10-21 | $1,349 M | Q2/20-Q2/23 | |
| Sun Pharmaceutical Industries | Octreotide | Octreotide | 2008-03-04 | |||
| Wockhardt | Octreotide | Octreotide | 2011-05-11 | |||
| Chiesi Farmaceutici | Octreotide | Mycapssa | 2029-09-17 | 2020-06-26 | ||
| Amryt Pharma | Octreotide | Mycapssa | 2022-12-02 | |||
| Heritage Pharmaceuticals | Octreotide | Octreotide | 2018-09-07 | |||
| West-Ward Pharmaceutical | Octreotide | Octreotide | 2005-03-28 | |||
| Fresenius Kabi | Octreotide | Octreotide | 2006-02-10 | |||
| Sagent Pharmaceuticals | Octreotide | Octreotide | 2013-11-12 |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
0%0/5
Phase 2
33%4/12
Phase 3
50%3/6
Approved: 1Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use